Most prescription drugs manufactured overseas—are they safe?

September 10, 2012

Most pharmaceutical drugs in Canada are manufactured overseas in countries such as India, China and others, yet how can we be confident the drug supply is safe, writes a drug policy researcher in an opinion piece in CMAJ (Canadian Medical Association Journal).

Alarmed by alerts about potentially harmful products such as nonprescription erectile dysfunction drugs with names like Uprizing 2.0 and Ying Da Wang—most from overseas—Alan Cassels began to think about sold in Canada. Are they safe? Who regulates them?

"Most Canadians probably don't know that many of our pharmaceuticals come from places like India and China," writes Cassels. "How often do our regulators dust off their passports and fly to China or India to ensure that the plants producing pharmaceuticals are clean, follow proper manufacturing techniques and contain what is on the label (and nothing else)?"

He was unable to find out much from Health Canada because information about inspections is not public.

"This situation doesn't leave me with the warm fuzzies," he writes. "Especially when we're dealing with—how can I say this nicely—a federal agency that refuses to even enforce the laws against illegal on a bus shelter at the end of my street?"

Explore further: CMAJ calls on federal government to protect Canadians from unsafe drugs

More information: www.cmaj.ca/lookup/doi/10.1503/cmaj.120416

Related Stories

CMAJ calls on federal government to protect Canadians from unsafe drugs

April 18, 2011
Canada needs to modernize its pharmaceutical drug laws to ensure that new drugs as well as older drugs are safe for Canadians, states an editorial in CMAJ (Canadian Medical Association Journal).

Safe prescribing information for children in Canada often hard to find

June 13, 2011
Accurate, safe prescribing information for children is often unavailable to doctors in Canada because pharmaceutical companies will not disclose information to Health Canada, states an editorial in CMAJ (Canadian Medical ...

Canadians should demand commitments for pharmacare program, says CMAJ

April 26, 2011
Canada needs a national pharmacare program and federal leaders must commit adequate funding, states an editorial in CMAJ (Canadian Medical Association Journal).

Female feticide in Canada requires action

January 16, 2012
Canada should prohibit disclosure of the sex of a fetus until after 30 weeks of pregnancy to combat female feticide which is practised by some ethnic groups in Canada and the United States, states an editorial in CMAJ (Canadian ...

Pharmaceutical intellectual property laws need reform

November 7, 2011
Canada's pharmaceutical intellectual property laws need major reform to encourage and protect innovation in developing new drugs, states an analysis in CMAJ (Canadian Medical Association Journal).

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.